Page 105 - 《中国药房》2022年3期
P. 105

性原则[J].中国临床药理学与治疗学,2021,26(4):449-                 primary dysmenorrhoea[J]. J Obstet Gynaecol,2018,38
             453.                                               (6):828-832.
        [17]  HERNÁN M A,ROBINS J M. Per-protocol analyses of  [28]  SCHINDLER A E,CAMPAGNOLI C,DRUCKMANN R,
             pragmatic trials[J]. N Engl J Med,2017,377(14):1391-  et al. Classification and pharmacology of progestins[J].
             1398.                                              Maturitas,2008,61(1/2):171-180.
        [18]  COX D J,MEYER R G. Behavioral treatment parameters  [29]  CROMER B A,STAGER M,BONNY A,et al. Depot me-
             with primary dysmenorrhea[J]. J Behav Med,1978,1(3):  droxyprogesterone acetate,oral contraceptives and bone
             297-310.                                           mineral density in a cohort of adolescent girls[J]. J Ado-
        [19]  马玉侠,马海洋,陈少宗,等.中文版 COX 痛经症状量表                      lesc Health,2004,35(6):434-441.
             的信效度检验[J].山东中医药大学学报,2015,39(1):               [30]  马玉侠,衣华强,孙玉国,等.痛经相关测评量表与评估方
             5-7.                                               法研究进展[J].山东中医药大学学报,2009,33(4):347-
        [20]  LINS L,CARVALHO F M. SF-36 total score as a single  348.
             measure of health-related quality of life:scoping review  [31]  MOMOEDA M,AKIYAMA S,TANAKA K,et al. Quality
             [J]. SAGE Open Med,2016,4:1-12.                    of life in Japanese patients with dysmenorrhea treated
        [21]  STULL D E,WASIAK R,KREIF N,et al. Validation of   with ethinylestradiol 20 μg/drospirenone 3 mg in a real-
             the SF-36 in patients with endometriosis[J]. Qual Life  world setting:an observational study[J]. Int J Womens
             Res,2014,23(1):103-117.                            Health,2020,12:327-338.
        [22]  LEVY-ZAUBERMAN Y,POURCELOTA G,CAPMAS P,      [32]  FOURNIER A,BERRINO F,CLAVEL-CHAPELON F.
             et al. Update on the management of abnormal uterine  Unequal risks for breast cancer associated with different
             bleeding[J]. J Gynecol Obstet Hum Reprod,2017,46(8):  hormone replacement therapies:results from the E3N
             613-622.                                           cohort study[J]. Breast Cancer Res Treat,2008,107(1):
        [23]  TANIGUCHI F,OTA I,IBA Y,et al. The efficacy and   103-111.
             safety of dydrogesterone for treatment of dysmenorrhea:  [33]  吴珂.温针灸联合痛经宁颗粒治疗原发性痛经效果及对
             an open-label multicenter clinical study[J]. J Obstet  血清 CA125 及子宫动脉血流动力学的影响[J].光明中
             Gynaecol Res,2019,45(1):168-175.                   医,2021,36(13):2178-2180.
        [24]  蒲宝婵,姜国云,方玲.原发性痛经疼痛因子及其关联性                    [34]  张卫平.艾芪汤治疗原发性痛经的疗效观察及对血清
             研究[J].中华中医药学刊,2014,32(6):1368-1370.                PGF2α、IL-6 含量的影响[J].中国中医药科技,2021,28
        [25]  MESIANO S. Myometrial progesterone responsiveness[J].  (1):63-64.
             Semin Reprod Med,2007,25(1):5-13.             [35]  VELASCO I,ACIÉN P,CAMPOS A,et al. Interleukin-6
        [26]  YASUDA K,SUMI G I,MURATA H,et al. The steroid     and other soluble factors in peritoneal fluid and endometrio-
             hormone dydrogesterone inhibits myometrial contraction  mas and their relation to pain and aromatase expression
             independently of the progesterone/progesterone receptor  [J]. J Reprod Immunol,2010,84(2):199-205.
             pathway[J]. Life Sci,2018,207:508-515.                       (来稿日期:2021-08-25  修回日期:2021-10-27)
        [27]  UYSAL G,AKKAYA H,CAGLI F,et al. A comparison of                                   (编辑:舒安琴)
             two different oral contraceptives in patients with severe









                  《中国药房》杂志——中国科技核心期刊,欢迎投稿、订阅















        中国药房    2022年第33卷第3期                                               China Pharmacy 2022 Vol. 33 No. 3  ·351 ·
   100   101   102   103   104   105   106   107   108   109   110